Who are D-chiro-inositol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metformin / clomid / hCG, Drospirenone Ethinyl estradiol Myo-inositol, MSDC-0602K.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/d-chiro-inositol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

D-chiro-inositol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

D-chiro-inositol (D-chiro-inositol) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin sensitizer. Area: Metabolic disorders.

phase 2 Insulin sensitizer Metabolic disorders Small molecule Live · refreshed every 30 min

Target snapshot

D-chiro-inositol (D-chiro-inositol) — Biosearch S.A.. D-chiro-inositol is involved in insulin signaling and glucose metabolism.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
D-chiro-inositol TARGET	D-chiro-inositol	Biosearch S.A.	phase 2	Insulin sensitizer
Metformin / clomid / hCG	Metformin / clomid / hCG	The Egyptian IVF-ET Center	marketed	Combination fertility agent (insulin sensitizer + ovulation inducer + gonadotropin)
Drospirenone Ethinyl estradiol Myo-inositol	Drospirenone Ethinyl estradiol Myo-inositol	AGUNCO Obstetrics and Gynecology Centre	marketed	Oral contraceptive with insulin sensitizer	Progesterone receptor, estrogen receptor, inositol signaling pathway
MSDC-0602K	MSDC-0602K	Cirius Therapeutics, Inc.	phase 3	Mitochondrial pyruvate carrier activator / Thiazolidinedione-like insulin sensitizer	Mitochondrial pyruvate carrier (MPC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin sensitizer class)

Biosearch S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). D-chiro-inositol — Competitive Intelligence Brief. https://druglandscape.com/ci/d-chiro-inositol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing